CA-19-9 IN NONNEOPLASTIC LIVER-DISEASES - A CLINICAL AND LABORATORY STUDY

被引:31
作者
COLLAZOS, J
GENOLLA, J
RUIBAL, A
机构
[1] HOSP CRUCES, NUCL MED SERV, VIZCAYA, SPAIN
[2] HOSP GEN ASTURIAS, NUCL MED SERV, OVIEDO, SPAIN
关键词
CA-19-9; CARBOHYDRATE ANTIGENS; FALSE POSITIVE RESULTS; BENIGN LIVER DISEASES; TUMOR MARKERS; CIRRHOSIS;
D O I
10.1016/0009-8981(92)90053-S
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
CA 19-9 is a tumor marker with frequent false-positive results in pancreatic and hepatobiliary diseases. This study was carried out to evaluate the behaviour of CA 19-9 in 159 patients with benign diffuse hepatic disease, 85 cirrhotics and 74 non-cirrhotics, who underwent a thorough clinical and laboratory evaluation. CA 19-9 was correlated with numerous clinical and biochemical features of liver diseases: bilirubin and alkaline phosphatase activity were the most reliable predictors of the CA 19-9 concentrations. There were abnormal concentrations of CA 19-9 in 34.6% of the 159 patients and in 47.1% of the 85 cirrhotics. Because of the large number of abnormal values and the high concentrations attained in some of them, the cut-off used in patients with diffuse hepatic disease needs to be set at more than twice the basal level, thus allows only 10% of false positives. Even higher values are required for cirrhotic or icteric patients. The results indicate that cholestasis plays an important role in causing the raised CA 19-9 in these patients, although there were also abnormal concentrations in normobilirubinemic patients.
引用
收藏
页码:145 / 151
页数:7
相关论文
共 17 条
[1]   PROSPECTIVE EVALUATION OF THE DIAGNOSTIC EFFICACY OF CA 19-9 ASSAY AS A MARKER FOR GASTROINTESTINAL CANCERS [J].
ANDRIULLI, A ;
GINDRO, T ;
PIANTINO, P ;
FARINI, R ;
CAVALLINI, G ;
PIAZZI, L ;
NACCARATO, R ;
DOBRILLA, G ;
VERME, G ;
SCURO, LA .
DIGESTION, 1986, 33 (01) :26-33
[2]  
ARAKAWA Y, 1985, JPN J MED, V24, P121
[3]  
Barone D, 1988, Int J Biol Markers, V3, P95
[4]  
BRUNS M, 1986, 4 HAMB S TUM STUTTG, P32
[5]  
CHILD GC, 1964, LIVER PORTAL HYPERTE, P50
[6]  
ENCABO G, 1986, B CANCER, V73, P256
[7]  
FABRIS C, 1991, CANCER-AM CANCER SOC, V68, P1795, DOI 10.1002/1097-0142(19911015)68:8<1795::AID-CNCR2820680824>3.0.CO
[8]  
2-I
[9]  
FUKUDA Y, 1986, AM J GASTROENTEROL, V81, P1149
[10]   NEW CARBOHYDRATE TUMOR-MARKERS [J].
ITZKOWITZ, SH ;
KIM, YS .
GASTROENTEROLOGY, 1986, 90 (02) :491-494